Cargando…

Advances in oral peptide drug nanoparticles for diabetes mellitus treatment

Peptide drugs play an important role in diabetes mellitus treatment. Oral administration of peptide drugs is a promising strategy for diabetes mellitus because of its convenience and high patient compliance compared to parenteral administration routes. However, there are a series of formidable unfav...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Yan, Zhang, Wen, Zhao, Ruichen, Zhang, Xin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: KeAi Publishing 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8958389/
https://www.ncbi.nlm.nih.gov/pubmed/35386357
http://dx.doi.org/10.1016/j.bioactmat.2022.02.025
_version_ 1784676933354651648
author Li, Yan
Zhang, Wen
Zhao, Ruichen
Zhang, Xin
author_facet Li, Yan
Zhang, Wen
Zhao, Ruichen
Zhang, Xin
author_sort Li, Yan
collection PubMed
description Peptide drugs play an important role in diabetes mellitus treatment. Oral administration of peptide drugs is a promising strategy for diabetes mellitus because of its convenience and high patient compliance compared to parenteral administration routes. However, there are a series of formidable unfavorable conditions present in the gastrointestinal (GI) tract after oral administration, which result in the low oral bioavailability of these peptide drugs. To overcome these challenges, various nanoparticles (NPs) have been developed to improve the oral absorption of peptide drugs due to their unique in vivo properties and high design flexibility. This review discusses the unfavorable conditions present in the GI tract and provides the corresponding strategies to overcome these challenges. The review provides a comprehensive overview on the NPs that have been constructed for oral peptide drug delivery in diabetes mellitus treatment. Finally, we will discuss the rational application and give some suggestions that can be utilized for the development of oral peptide drug NPs. Our aim is to provide a systemic and comprehensive review of oral peptide drug NPs that can overcome the challenges in GI tract for efficient treatment of diabetes mellitus.
format Online
Article
Text
id pubmed-8958389
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher KeAi Publishing
record_format MEDLINE/PubMed
spelling pubmed-89583892022-04-05 Advances in oral peptide drug nanoparticles for diabetes mellitus treatment Li, Yan Zhang, Wen Zhao, Ruichen Zhang, Xin Bioact Mater Review Article Peptide drugs play an important role in diabetes mellitus treatment. Oral administration of peptide drugs is a promising strategy for diabetes mellitus because of its convenience and high patient compliance compared to parenteral administration routes. However, there are a series of formidable unfavorable conditions present in the gastrointestinal (GI) tract after oral administration, which result in the low oral bioavailability of these peptide drugs. To overcome these challenges, various nanoparticles (NPs) have been developed to improve the oral absorption of peptide drugs due to their unique in vivo properties and high design flexibility. This review discusses the unfavorable conditions present in the GI tract and provides the corresponding strategies to overcome these challenges. The review provides a comprehensive overview on the NPs that have been constructed for oral peptide drug delivery in diabetes mellitus treatment. Finally, we will discuss the rational application and give some suggestions that can be utilized for the development of oral peptide drug NPs. Our aim is to provide a systemic and comprehensive review of oral peptide drug NPs that can overcome the challenges in GI tract for efficient treatment of diabetes mellitus. KeAi Publishing 2022-02-28 /pmc/articles/PMC8958389/ /pubmed/35386357 http://dx.doi.org/10.1016/j.bioactmat.2022.02.025 Text en © 2022 The Authors https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Review Article
Li, Yan
Zhang, Wen
Zhao, Ruichen
Zhang, Xin
Advances in oral peptide drug nanoparticles for diabetes mellitus treatment
title Advances in oral peptide drug nanoparticles for diabetes mellitus treatment
title_full Advances in oral peptide drug nanoparticles for diabetes mellitus treatment
title_fullStr Advances in oral peptide drug nanoparticles for diabetes mellitus treatment
title_full_unstemmed Advances in oral peptide drug nanoparticles for diabetes mellitus treatment
title_short Advances in oral peptide drug nanoparticles for diabetes mellitus treatment
title_sort advances in oral peptide drug nanoparticles for diabetes mellitus treatment
topic Review Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8958389/
https://www.ncbi.nlm.nih.gov/pubmed/35386357
http://dx.doi.org/10.1016/j.bioactmat.2022.02.025
work_keys_str_mv AT liyan advancesinoralpeptidedrugnanoparticlesfordiabetesmellitustreatment
AT zhangwen advancesinoralpeptidedrugnanoparticlesfordiabetesmellitustreatment
AT zhaoruichen advancesinoralpeptidedrugnanoparticlesfordiabetesmellitustreatment
AT zhangxin advancesinoralpeptidedrugnanoparticlesfordiabetesmellitustreatment